Aspen Pharmacare has announced the sale of the European commercialisation rights, marketing authorisations, product registrations, and intellectual property for its women’s health product, Ovestin, to Ennogen.
The deal includes an additional €4 million ($4.5 million) for existing inventory, bringing the initial transaction value to roughly €201 million. Pending the finalisation of Ennogen’s financing, the transaction valuation represents over five times Ovestin’s latest annual revenue (R756 million / ~$45 million) and 16 times its after-tax profit (R238 million / ~$14 million) for the financial year ending June 2026. Aspen expects to record a gain of approximately R2 billion ($120 million) on the sale, based on net assets valued at R1.6 billion.
Rather than exiting the brand entirely, Aspen will retain manufacturing responsibilities and continue supplying Ovestin’s active pharmaceutical ingredient and cream formulation to Ennogen under a 10-year agreement. Additionally, Aspen will provide strategic services for five years at €1 million per month (potentially generating €60 million / ~$67 million) and collect a 4% royalty on net sales through a three-year transitional distribution arrangement.
Key details of the agreement include:
* **No Staff Transfers:** No employees will be transferred to Ennogen, and Aspen’s production facilities will stay active in the European supply chain.
* **Buyer Profile:** Founded in 2011, Ennogen is a privately held pharmaceutical and medical-device company headquartered in Dubai with presence in the UK and Ireland. Its beneficial owners remain undisclosed, though Aspen confirmed they are independent third parties.
This divestment aligns with Aspen’s broader corporate strategy to realize value from specific product lines and pivot its commercial presence toward emerging markets. It follows a major portfolio restructuring in May, where Aspen sold its non-China Asia-Pacific business for R28 billion. Driven by asset sales and improved cash flow, Aspen shifted from a net debt position of over R29 billion in 2025 to a net cash balance of R806 million by the end of FY2026. Following R500 million in share repurchases over the past year, Aspen indicated that proceeds from the Ovestin sale may also be allocated toward future share buybacks.
